Novabay Pharmaceuticals, INC 8-K filings
NovaBay Pharmaceuticals has accepted a revised offer from PRN Physician Recommended Nutriceuticals, increasing the purchase price for its eyecare business to $11.5 million and entering into an amendment to the asset purchase agreement.
NovaBay Pharmaceuticals has determined an unsolicited offer from Refresh Acquisitions to purchase its Avenova assets is superior to its existing agreement with PRN, potentially leading to a termination of the PRN deal.
8-K: NovaBay Pharmaceuticals Announces Preliminary Cash Position Ahead of Special Stockholder Meeting
NovaBay Pharmaceuticals reports a preliminary unaudited cash balance of $776,000 as of September 30, 2024, in connection with its upcoming special stockholder meeting to approve the sale of its eyecare assets and potential dissolution.
NovaBay Pharmaceuticals has agreed to sell its Avenova brand assets to PRN Physician Recommended Nutriceuticals for $9.5 million in cash and intends to liquidate the company following the sale.
8-K: NovaBay Pharmaceuticals Completes $3.87 Million Public Offering to Redeem Debt and Fund Operations
NovaBay Pharmaceuticals successfully closed a public offering, raising $3.87 million to redeem debt and support working capital.
NovaBay Pharmaceuticals reports preliminary second quarter 2024 net revenue of $2.4 million, with eyecare revenue increasing by 9% compared to the same period last year.
NovaBay Pharmaceuticals has entered into agreements with existing warrant holders to reprice and exercise warrants, resulting in new warrant issuances and approximately $225,952 in gross proceeds.
NovaBay Pharmaceuticals has received approval from NYSE American for its plan to regain compliance with continued listing standards, granting them until October 18, 2025, to meet the requirements.
NovaBay Pharmaceuticals has completed a 1-for-35 reverse stock split, effective May 30, 2024, to maintain its NYSE American listing.
NovaBay Pharmaceuticals has filed pro forma financial statements reflecting the sale of its DERMAdoctor subsidiary, providing a view of the company's financials as if the divestiture had occurred earlier.
NovaBay Pharmaceuticals received a second notice from the NYSE American for failing to meet minimum stockholders' equity requirements, despite shareholder approval of a 1-for-35 reverse stock split.
NovaBay Pharmaceuticals released a corporate update presentation on April 22, 2024, detailing its operational progress and business strategy.
8-K: NovaBay Pharmaceuticals Faces NYSE American Delisting Threat Due to Stockholder Equity Deficiency
NovaBay Pharmaceuticals has received a notice from the NYSE American stating that it is not in compliance with minimum stockholder equity requirements and must submit a plan to regain compliance.
NovaBay Pharmaceuticals finalized the sale of its DERMAdoctor subsidiary for $1.07 million, issuing new warrants and convertible notes as part of the transaction.
NovaBay Pharmaceuticals has amended its security agreement and is set to sell its DERMAdoctor subsidiary for $1.07 million, pending certain conditions.
NovaBay Pharmaceuticals is selling its DERMAdoctor skincare business for $1.07 million to reduce operating expenses and focus on its core eyecare business.